在接受佩格维索曼特治疗的壮病患者中与疾病控制失败相关的因素:ACROSTUDY分析分析
Antonella Giampietro1, Sabrina Chiloiro1, Claudio Urbani2
1Pituitary Unit, Department of Endocrinology, Fondazione A Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Endocrine connections
|January 10, 2024
概括
胰岛素样生长因子-1 (IGF-1) 基线水平是用Pegvisomant对长期壮症控制的关键预测指标. 其他因素,如年龄或剂量没有显著影响治疗结果.
科学领域:
- 内分泌学 在内分泌学.
- 药物治疗 药物治疗
- 临床研究 临床研究
背景情况:
- 巨症是一种慢性内分泌疾病,由多余的生长激素引起.
- 有效的疾病控制对于预防长期并发症至关重要.
- 佩格维索曼 (Pegvisomant) 是一种生长激素受体抗剂,用于壮症治疗.
研究的目的:
- 调查患者,疾病和与治疗相关的因素,这些因素会影响在佩格维索曼特治疗期间的壮病控制.
- 根据各种共同变量来确定实现疾病控制的纵向概率.
主要方法:
- 来自ACROSTUDY数据的分析,这是一项15个国家进行的非干预性,营销后安全性研究.
- 包括1546名接受佩格维索曼特治疗的壮病患者与基线IGF-1数据.
- 影响IGF-1控制的因素的纵向评估,使用10年混合效应逻辑回归.
主要成果:
- 较低的IGF-1基线水平 (<300μg/L) 与不受控制的巨病的最低风险相关 (ES=0.29).
- 基线IGF-1水平在300-500μg/L之间也显示出失控的风险较低 (ES=0.37).
- 较高的IGF-1基线水平 (≥700μg/L) 表明失控壮症的风险更大 (ES=0.58).
结论:
- 基线IGF-1水平是治疗佩格维索曼特的患者长期壮症控制的重要预测指标.
- 年龄,性别,BMI和pegvisomant剂量没有被发现是长期疾病控制的重要预测因素.
相关概念视频
01:15Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
01:27Adrenal Gland Disorders
1.5K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.5K
01:20Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432